H1N1 Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The H1N1 Vaccines market is segmented By Product Type (Inactivated Vaccine, Live Attenuated Vaccine), By Route of Administration and Geography.

H1N1 Vaccines Market Snapshot

H1N1 Vaccines Market CAGR
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The H1N1 Vaccines Market is expected to register a CAGR of 5.2% during the forecast period. The H1N1 virus, commonly known as swine flu is an infectious disease in humans caused by the swine H1N1 virus, which is characterized by a persistent cough, cold, high fever, red watery eyes, body aches, headache, and general discomfort. H1N1 virus affects various species such as swine, birds, horses and other animals. The H1N1 virus is contagious and can spread widely through small droplets of saliva from coughs or sneezes of infected person. H1N1 virus causes damage to the respiratory system including nose, lungs, and throat. The H1N1 virus is a Ribonucleic acid (RNA) virus belonging to the Orthomyxoviridae family. In the year 2009, a strain of swine flu called "H1N1" infected many people around the world.

According to the World Health Organization (WHO), annually about 3 to 5 million cases of severe illness and about 2,90,000 to 6,50,000 respiratory deaths are due to seasonal influenza. In the case of industrialized countries, most of the deaths due to influenza occur among people above 65 years of age. Seasonal influenza illnesses range from mild to severe and even death.

Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population and technological advancements in the vaccines are the key driving factors in the H1N1 vaccines market.

Scope of the Report

The H1N1 virus, commonly known as swine flu is an infectious disease in humans caused by the swine H1N1 virus, which is characterized by a persistent cough, cold, high fever, red watery eyes, body aches, headache, and general discomfort. H1N1 Vaccines Market is segmented By Product Type, By Route of Administration and Geography.

By Product Type
Inactivated Vaccine
Live Attenuated Vaccine
By Route of Administration
Intradermal Vaccines
Intramuscular Vaccines
Intranasal Vaccines
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Intramuscular Vaccines Segment is Expected to Witness a Rapid Growth

An intramuscular injection is a procedure used to deliver a medication deep into the muscles which allows the medication to be absorbed into the bloodstream quickly. Intramuscular injections are absorbed faster than subcutaneous injections because muscles have a greater blood supply than the tissue present under the skin. Moreover, muscle tissue can also hold a larger volume of medication than subcutaneous tissue. According to the 2017 United Nations report, the global population is crossing the age of 60 at an annual rate of 3% which maximizes the risk of various diseases such as respiratory tract disorders and immune deficient diseases, thereby the risk for infection due to H1N1 virus rises.

The intramuscular vaccines segment holds a significant market share in the H1N1 vaccines market and is anticipated to show a similar trend over the forecast period. Rising incidences of swine flu and the need for H1N1 vaccination is increasing and  increased risk of respiratory diseases and immune-deficient diseases among the geriatric population are the key driving factors in the intramuscular vaccines segment.

H1N1 Vaccines Market key trend 1

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the H1N1 vaccines market due to increasing government initiatives for the prevention of H1N1 infection and improved research infrastructure in this region. According to the Centers for Disease Control (CDC), about 8 percent of the United States population gets sick from the flu. In addition, approximately 31.4 million people visit the doctor and 200,000 people end up in the hospital every flu season. Moreover, technological advancements in the vaccines field and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

H1N1 Vaccines Market 2

Competitive Landscape

The H1N1 Vaccines Market is consolidated and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are MedImmune LLC (AstraZeneca PLC), Sanofi Pasteur AG, GlaxoSmithKline Plc, Abbott Laboratories, CSL Limited (Seqirus GmbH), Pfizer Inc, CPL Biologicals Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Sinovac Biotech Ltd and Zydus Cadila.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidences of Epidemic H1N1 Infection and Declining Immunity Among people

      2. 4.2.2 Technological Advancements in the Vaccines Field

    3. 4.3 Market Restraints

      1. 4.3.1 High costs of H1N1 Vaacines

      2. 4.3.2 Lengthy Manufacturing Process of H1N1 Vaacines

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product Type

      1. 5.1.1 Inactivated Vaccine

      2. 5.1.2 Live Attenuated Vaccine

    2. 5.2 By Route of Administration

      1. 5.2.1 Intradermal Vaccines

      2. 5.2.2 Intramuscular Vaccines

      3. 5.2.3 Intranasal Vaccines

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 MedImmune LLC (AstraZeneca PLC)

      2. 6.1.2 Sanofi Pasteur AG

      3. 6.1.3 GlaxoSmithKline Plc

      4. 6.1.4 Abbott Laboratories

      5. 6.1.5 CSL Limited (Seqirus GmbH)

      6. 6.1.6 Pfizer Inc

      7. 6.1.7 CPL Biologicals Pvt. Ltd

      8. 6.1.8 Mitsubishi Tanabe Pharma Corporation

      9. 6.1.9 Sinovac Biotech Ltd

      10. 6.1.10 Zydus Cadila

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The H1N1 Vaccines Market market is studied from 2018 - 2026.

The H1N1 Vaccines Market is growing at a CAGR of 5.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

AstraZeneca Plc, Sanofi (Sanofi Pasteur AG), GlaxoSmithKline Plc, Abbott Laboratories, CSL Limited (Seqirus GmbH) are the major companies operating in H1N1 Vaccines Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!